Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 14 1010 / https://doi.org/10.3332/ecancer.2020.1010

Case Report

Slowly developing toxic epidermal necrolysis-like reaction associated with pemetrexed and carboplatin

Most cutaneous adverse drug reactions reported in association with chemotherapy, such as a limited maculopapular rash, are considered mild and do not affect the continuation of the treatment. Toxic epidermal necrolysis (TEN), however, is a life-threatening reaction that needs treatment discontinuation. The present case shows the slow progression from a pemetrexed and carboplatin-associated maculopapular rash to a TEN-like reaction.

Keywords: toxic epidermal necrolysis, cutaneous adverse drug reactions, drug rash, pemetrexed

Loading Article Metrics ... Please wait

Related articles

Short Communication: COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?

Abstract | Full Article | PDF Published: 30 Mar 2020 / https://doi.org/10.3332/ecancer.2020.1023

Review: Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence

Abstract | Full Article | PDF Published: 27 Mar 2020 / https://doi.org/10.3332/ecancer.2020.1022

Clinical Study: Prospective study to assess the survival outcomes of planned irradiation of ipsilateral subventricular and periventricular zones in glioblastoma

Abstract | Full Article | PDF Published: 26 Mar 2020 / https://doi.org/10.3332/ecancer.2020.1021

Research: Impact of HER2 status in resected gastric or gastroesophageal junction adenocarcinoma in a Western population

Abstract | Full Article | PDF | Español Published: 24 Mar 2020 / https://doi.org/10.3332/ecancer.2020.1020

Clinical Study: Sequential chemotherapy followed by radical thoracic radiotherapy (50 Gy in 25 fractions) in limited stage small cell lung cancer

Abstract | Full Article | PDF Published: 09 Mar 2020 / https://doi.org/10.3332/ecancer.2020.1019



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation